Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In this episode of the Big Questions podcast, Dr Andy Segerdahl (Wellcome Centre for Integrative Neuroimaging and Nuffield Department of Clinical Neurosciences) explains his research looking at how the brain and spinal cord process pain.

None

We all feel pain differently. What to one person may be the worst pain in the world, might be a mild irritation to another person; but why? At the moment, we don’t have a thorough understanding of how pain is processed, meaning it is difficult to devise treatments for chronic (long-term) pain.

In this episode of the ‘Big Questions’ podcast, we are lucky enough to join Dr Andy Segerdahl – a neuroscientist at the Wellcome Centre for Integrative Neuroimaging (WIN) and the Nuffield Department of Clinical Neurosciences at the University of Oxford – for one of his experiments, where he is examining pain response (in a willing volunteer!) using an fMRI scanner. As he explains, if we can fully understand which parts of the brain and spinal cord are involved in pain response in a healthy individual, we can begin to understand how this response becomes dysfunctional.

Listen to the podcast on the Oxford Sparks website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.